{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:09:41Z","timestamp":1793052581558,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.biomaterials.2021.120791","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T19:42:54Z","timestamp":1617306174000},"page":"120791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"special_numbering":"C","title":["Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity"],"prefix":"10.1016","volume":"272","author":[{"given":"Suah","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Kyu","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwoong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Hoon","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongrae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujeong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-9272","authenticated-orcid":false,"given":"Han Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-San","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-188X","authenticated-orcid":false,"given":"Kwangmeyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biomaterials.2021.120791_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2021.120791_bib2","first-page":"365","article-title":"Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients, Cancer Immunology","volume":"69","author":"Ma","year":"2020","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.biomaterials.2021.120791_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2021.120791_bib4","doi-asserted-by":"crossref","first-page":"119264","DOI":"10.1016\/j.biomaterials.2019.119264","article-title":"Synergistic triple-combination therapy with hyaluronic acid-shelled PPy\/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer","volume":"217","author":"Sun","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2021.120791_bib5","doi-asserted-by":"crossref","first-page":"119469","DOI":"10.1016\/j.biomaterials.2019.119469","article-title":"The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy","volume":"223","author":"Hu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2021.120791_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.biomaterials.2018.04.027","article-title":"Combinational strategy for high-performance cancer chemotherapy","volume":"171","author":"Qin","year":"2018","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.biomaterials.2021.120791_bib7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2021.120791_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/cmi.2013.59","article-title":"TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells","volume":"11","author":"Fang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"issue":"1739","key":"10.1016\/j.biomaterials.2021.120791_bib9","article-title":"Combining immune checkpoint inhibitors with conventional cancer therapy","volume":"9","author":"Yan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2021.120791_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2017.35.15_suppl.556","article-title":"Pembrolizumab and chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC)","volume":"35","author":"Schmid","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biomaterials.2021.120791_bib11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biomaterials.2021.120791_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jconrel.2020.10.065","article-title":"Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance","volume":"330","author":"Kim","year":"2020","journal-title":"J. Contr. Release"},{"issue":"22","key":"10.1016\/j.biomaterials.2021.120791_bib13","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1158\/0008-5472.CAN-15-3034","article-title":"Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage","volume":"76","author":"Wang","year":"2016","journal-title":"Canc. Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2021.120791_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejheart.2008.01.004","article-title":"Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice","volume":"10","author":"Riad","year":"2008","journal-title":"Eur. J. Heart Fail."},{"issue":"370","key":"10.1016\/j.biomaterials.2021.120791_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti\u2013PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"25","key":"10.1016\/j.biomaterials.2021.120791_bib16","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.7150\/thno.38425","article-title":"Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy","volume":"9","author":"Lim","year":"2019","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.biomaterials.2021.120791_bib17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/anie.201804882","article-title":"Nanoparticle-Mediated immunogenic cell death enables and potentiates cancer immunotherapy","volume":"58","author":"Duan","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2021.120791_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biomaterials.2016.06.032","article-title":"Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy","volume":"102","author":"Zhao","year":"2016","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.biomaterials.2021.120791_bib19","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.120791_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention, JNCI","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.120791_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-3659(97)00235-6","article-title":"Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate","volume":"53","author":"Omelyanenko","year":"1998","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.biomaterials.2021.120791_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2003.07.001","article-title":"Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer\u2013doxorubicin conjugates to human colon cancer cells","volume":"40","author":"David","year":"2004","journal-title":"Eur. J. Canc."},{"issue":"5","key":"10.1016\/j.biomaterials.2021.120791_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejps.2011.03.001","article-title":"Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting","volume":"42","author":"Etrych","year":"2011","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2021.120791_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00124-2","article-title":"Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine","volume":"57","author":"Julyan","year":"1999","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.biomaterials.2021.120791_bib25","first-page":"7","article-title":"Doxorubicin-Polymer conjugates: further demonstration of the concept of enhanced permeability and retention","volume":"5","author":"Muggia","year":"1999","journal-title":"Clin. Canc. Res."},{"issue":"24","key":"10.1016\/j.biomaterials.2021.120791_bib26","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1021\/jm0101996","article-title":"The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy","volume":"44","author":"Garsky","year":"2001","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.120791_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0959-8049(00)00374-9","article-title":"Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer\u2013doxorubicin conjugates in nude mice","volume":"37","author":"Shiah","year":"2001","journal-title":"Eur. J. Canc."},{"issue":"2","key":"10.1016\/j.biomaterials.2021.120791_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/ijo.2012.1754","article-title":"Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy","volume":"42","author":"Zhong","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.biomaterials.2021.120791_bib29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1517\/13543784.16.7.1037","article-title":"Anticancer carrier-linked prodrugs in clinical trials","volume":"16","author":"Kratz","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.biomaterials.2021.120791_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2021.120791_bib31","series-title":"Cancer-specific Drug-Drug Nanoparticles of Pro-apoptotic and Cathepsin B-Cleavable Peptide-Conjugated Doxorubicin for Drug-Resistant Cancer Therapy","first-page":"120347","author":"Shim","year":"2020"},{"key":"10.1016\/j.biomaterials.2021.120791_bib32","doi-asserted-by":"crossref","first-page":"119494","DOI":"10.1016\/j.biomaterials.2019.119494","article-title":"Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy","volume":"224","author":"Um","year":"2019","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.biomaterials.2021.120791_bib33","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1021\/acsnano.7b07723","article-title":"Structural polymorphism in a self-assembled tri-aromatic peptide system","volume":"12","author":"Brown","year":"2018","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.biomaterials.2021.120791_bib34","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1021\/jp5077388","article-title":"Self-assembly of phenylalanine-based molecules","volume":"119","author":"German","year":"2015","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.biomaterials.2021.120791_bib35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jconrel.2018.11.032","article-title":"Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy","volume":"294","author":"Shim","year":"2019","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.biomaterials.2021.120791_bib36","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s11095-006-9104-4","article-title":"A review of poloxamer 407 pharmaceutical and pharmacological characteristics","volume":"23","author":"Dumortier","year":"2006","journal-title":"Pharmaceut. Res."},{"issue":"47","key":"10.1016\/j.biomaterials.2021.120791_bib37","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1002\/anie.201608504","article-title":"Cathepsin\u2005B-Specific metabolic precursor for In\u2005Vivo tumor-specific fluorescence imaging","volume":"55","author":"Shim","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.120791_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2008.11.019","article-title":"A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester","volume":"342","author":"Miksa","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.biomaterials.2021.120791_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14728222.2013.740461","article-title":"Cathepsin B as a cancer target","volume":"17","author":"Gondi","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4 Part 1","key":"10.1016\/j.biomaterials.2021.120791_bib40","first-page":"458","article-title":"On the chemical pathology of interstitial fluid","volume":"25","author":"Sylv\u00e9n","year":"1965","journal-title":"Canc. Res."},{"issue":"11","key":"10.1016\/j.biomaterials.2021.120791_bib41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1021\/jm00185a004","article-title":"Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity of L1210 leukemic cells in vitro and in vivo","volume":"23","author":"Baurain","year":"1980","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biomaterials.2021.120791_bib42","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3762\/bjnano.5.174","article-title":"Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages","volume":"5","author":"Kuhn","year":"2014","journal-title":"Beilstein J. Nanotechnol."},{"issue":"12","key":"10.1016\/j.biomaterials.2021.120791_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083239","article-title":"Peptide-Mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models","volume":"8","author":"Chang","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.biomaterials.2021.120791_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"18","key":"10.1016\/j.biomaterials.2021.120791_bib45","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.7150\/thno.45391","article-title":"Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.biomaterials.2021.120791_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1939-1676.1992.tb00352.x","article-title":"Hematologic toxicosis associated with doxorubicin administration in cats","volume":"6","author":"O'Keefe","year":"1992","journal-title":"J. Vet. Intern. Med."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221001472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221001472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:59:50Z","timestamp":1758905990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961221001472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":46,"alternative-id":["S0142961221001472"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120791","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120791"}}